8 results about "CD36" patented technology

This invention discloses the application of reagents for detecting biomarker levels in the preparation of products for identifying obstructive sleep apnea. It relates to the field of biomarker technology and aims to overcome the shortcomings of existing technologies that rely on complex polysomnography (PSG) procedures, poor patient compliance, and a lack of effective molecular markers. The biomarkers used in this application consist of CD36 glycoprotein, 9-octadecenal, and protocatechuic acid 3-O-sulfate. This invention enables rapid and objective identification of obstructive sleep apnea by detecting the levels of the above biomarkers in plasma. The procedure is simple and well-accepted by patients. The combined use of multiple biomarkers can improve the accuracy and stability of the identification, making it suitable for screening or auxiliary diagnosis in medical institutions at different levels.

The present application provides siRNA and its application for specifically inhibiting CD36 gene expression. In particular, the present application provides siRNA, shRNA, recombinant vector, recombinant lentivirus, siRNA, host cell for specifically inhibiting CD36 gene expression, and its application in preparing a medicament for inhibiting CD36 gene expression / treating CD36 related diseases.

The application discloses a kind of magnetic nanoparticles for atherosclerosis diagnosis and treatment.It is core-shell structure, the inner core is Fe₃O₄ magnetic nano material, shell is the drug-loading layer of biodegradable polymer material, the drug-loading layer is encapsulated with analog movement polypeptide K271la, and the surface of nano particle is covalently coupled with CD36 targeting antibody.Its preparation method mainly includes: by complex emulsification-solvent volatilization method, Fe₃O₄ nanoparticle and K271la polypeptide are co-encapsulated in one step, form nanoparticle, and then CD36 antibody is modified on the surface of particle by chemical coupling.The nanoparticle of the application has the ability of active targeting (CD36 antibody) and passive targeting (magnetic response), can be efficiently enriched in plaque, and deliver therapeutic polypeptide to macrophages, activate lipophagy to remove lipid;It can be used as magnetic resonance imaging contrast agent, realizes diagnosis and treatment integration, and provides a new strategy for solving the problem of low efficiency of atherosclerosis targeted therapy and lack of effective monitoring means.

The claimed invention relates to treating cancer by targeting CD36, a fatty acid receptor. The claimed invention also relates to treating cancer metastases by targeting CD36. The invention involves using anti-CD36 antibodies as blockers or inhibitors of CD36 activity.

Provided are an siRNA specifically inhibiting CD36 gene expression and the use thereof. Particularly, provided are siRNA, shRNA, a recombinant vector, a recombinant lentivirus, and a host cell that specifically inhibit CD36 gene expression, and the use thereof in the preparation of a drug for inhibiting the CD36 gene expression / treating CD36-related diseases.

The application relates to the technical field of medical data processing, in particular to a Crohn's disease prediction method based on metabolism-immunity, which comprises a collection module, a peripheral blood and a colon mucosa biopsy sample of a subject are collected to obtain data; a prediction module, a Treg cell function index is calculated according to the data, a fatty acid oxidation pathway activation index is calculated; a Crohn's risk index is calculated and a result is output; the application takes an ALA-CPT1A / CD36-FAO-Treg cell function regulation axis as a core, quantitatively couples alpha-linolenic acid concentration, expression of a core molecule of an FAO pathway, a Treg cell function comprehensive index and a clinical correction factor, and sequentially constructs: a Treg cell function comprehensive index reflecting an immune core state; an FAO pathway synergistic activation index reflecting a regulation effect of metabolism on immunity; and prediction is realized in combination with the Treg cell function comprehensive index, the FAO index and clinical correction.

This invention discloses the application of ZFP36 as a target in anti-non-small cell lung cancer (NSCLC) drugs and pharmaceutical compositions, belonging to the field of biomedical technology. The invention upregulates ZFP36 expression or enhances its RNA-binding activity, utilizing the zinc finger domain composed of amino acids 115-148 of the ZFP36 protein to specifically bind to the ATTTA-type ARE motif of the FASN mRNA 3'UTR and promote target mRNA degradation, thereby downregulating the expression of FASN, lipid droplet-related proteins, and CD36, thus triple-inhibiting lipid droplet metabolism. Simultaneously, it inhibits CAF secretion of lipid carriers, blocking lipid transport and metabolic remodeling in the tumor microenvironment. This invention can inhibit NSCLC cell proliferation, induce apoptosis, and reverse chemotherapy resistance. It clarifies that ZFP36-related biomarkers can be used for lung cancer chemotherapy resistance subtyping and targeted efficacy prediction, providing a novel target and approach for precision treatment of NSCLC, and possessing excellent clinical translational value.